(Q46670479)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16123745%20AND%20SRC:MED&resulttype=core&format=json

6 January 2020

meta-analysis

0 references

title

The relative sensitivity of the Clinical Global Impressions Scale and the Brief Psychiatric Rating Scale in antipsychotic drug trials (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16123745%20AND%20SRC:MED&resulttype=core&format=json

6 January 2020

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16123745%20AND%20SRC:MED&resulttype=core&format=json

6 January 2020

author name string

Stefan Leucht

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16123745%20AND%20SRC:MED&resulttype=core&format=json

6 January 2020

language of work or name

English

0 references

publication date

1 February 2006

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16123745%20AND%20SRC:MED&resulttype=core&format=json

6 January 2020

published in

Neuropsychopharmacology

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16123745%20AND%20SRC:MED&resulttype=core&format=json

6 January 2020

volume

31

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16123745%20AND%20SRC:MED&resulttype=core&format=json

6 January 2020

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16123745%20AND%20SRC:MED&resulttype=core&format=json

6 January 2020

page(s)

406-412

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16123745%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1038/sj.npp.1300873

6 January 2020

exact match

0 references

cites work

The positive and negative syndrome scale (PANSS) for schizophrenia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300873

"Clinical Global Impressions" (ECDEU): some critical comments

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300873

7 January 2021

Amisulpride has a superior benefit/risk profile to haloperidol in schizophrenia: results of a multicentre, double-blind study (the Amisulpride Study Group).

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300873

7 January 2021

Long-term safety and efficacy of amisulpride in subchronic or chronic schizophrenia. Amisulpride Study Group.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300873

7 January 2021

A meta-analysis of the efficacy of second-generation antipsychotics

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300873

7 January 2021

Amisulpride versus haloperidol in treatment of schizophrenic patients--results of a double-blind study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300873

7 January 2021

A rating scale for depression

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300873

7 January 2021

The Clinical Global Impression-Schizophrenia scale: a simple instrument to measure the diversity of symptoms present in schizophrenia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300873

7 January 2021

Relative sensitivity of the Montgomery-Asberg depression rating scale, the Hamilton depression rating scale and the Clinical Global Impressions rating scale in antidepressant clinical trials: a replication analysis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300873

7 January 2021

Relative sensitivity of the Montgomery-Asberg Depression Rating Scale, the Hamilton Depression rating scale and the Clinical Global Impressions rating scale in antidepressant clinical trials

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300873

7 January 2021

Amisulpride, an unusual "atypical" antipsychotic: a meta-analysis of randomized controlled trials.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300873

7 January 2021

Improvement of acute exacerbations of schizophrenia with amisulpride: a comparison with haloperidol. PROD-ASLP Study Group

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300873

7 January 2021

A New Depression Scale Designed to be Sensitive to Change

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300873

7 January 2021

Amisulpride vs. risperidone in the treatment of acute exacerbations of schizophrenia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300873

7 January 2021

Amisulpride, and atypical antipsychotic, in the treatment of acute episodes of schizophrenia: a dose-ranging study vs. haloperidol. The Amisulpride Study Group

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300873

7 January 2021

Self-reported depressive symptom measures: sensitivity to detecting change in a randomized, controlled trial of chronically depressed, nonpsychotic outpatients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300873

7 January 2021

Amisulpride vs. risperidone in chronic schizophrenia: results of a 6-month double-blind study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300873

7 January 2021

One-year, low-dose neuroleptic study of in-patients with chronic schizophrenia characterised by persistent negative symptoms. Amisulpride v. haloperidol

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300873

7 January 2021

Dropout rates in randomised antipsychotic drug trials

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300873

7 January 2021

Amisulpride versus flupentixol in schizophrenia with predominantly positive symptomatology -- a double-blind controlled study comparing a selective D2-like antagonist to a mixed D1-/D2-like antagonist. The Amisulpride Study Group.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300873

7 January 2021